SCHEDULE 13G: Nantahala Capital Management Discloses 9.99% Stake in Senti Biosciences

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, has disclosed a 9.99% beneficial ownership stake in Senti Biosciences, Inc. as of December 31, 2024.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have filed a Schedule 13G with the SEC.
• The filing indicates beneficial ownership of 509,283 shares of Senti Biosciences, Inc. common stock.
• This represents 9.99% of the total outstanding shares of Senti Biosciences, Inc. as of December 31, 2024.
• The Reporting Persons hold shared voting power and shared dispositive power over all 509,283 shares.
• The shares were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of Senti Biosciences, Inc.
• The reported beneficial ownership includes 509,283 shares that may be acquired by the Reporting Persons within sixty days.
• Funds advised by Nantahala, specifically NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP, BLACKWELL PARTNERS LLC SERIES A, and NCP RFM LP, each have the right to receive or direct proceeds from more than five percent of the outstanding common stock beneficially owned by Nantahala.

Sentiment

Score: 5

Explanation: The document is a standard regulatory disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the issuer's performance or prospects. It simply reports an investment stake.

Future Outlook

The document does not provide any forward-looking statements or guidance from Senti Biosciences, Inc. or the reporting persons regarding the issuer's future performance or strategic direction.

Industry Context

This filing indicates a significant passive investment by Nantahala Capital Management, an investment adviser, in Senti Biosciences, Inc., a biotechnology company. Such disclosures are common in the investment landscape, reflecting institutional interest in specific sectors or companies. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake (9.99%) by Nantahala Capital Management could be viewed positively by other shareholders as it indicates institutional confidence in Senti Biosciences, Inc. However, as a passive investment, it does not imply active engagement or influence on company strategy.

Key Dates

Keywords

Senti Biosciences, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Institutional Investor, SEC Filing, Biotechnology, Healthcare